Chimeric Therapeutics Limited

—As of Sun 8 Nov 2026, 12:00 UTC

ASX:CHMHealthcare

Country Australia

PE (Fwd) •••

TSR 6Y CAGR (79.67%)

Div yield —

ROE —

Biotechnology

Beta (5Y) 0.90

PE TTM —

TSR TTM (99.00%)

Mkt cap A$0.354M

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

$0.0033

8.36%

(58.95%)

Hold 3|12|7|3|3

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.081

Revenue$M

0.038

0.042

0.044

0.047

0.051

0.054

0.057

0.060

0.066

0.071

0.088

6.92%

7.06%

6

3.16

Revenue growth%

27.30

27.14

27.72

28.66

29.88

29.25

26.51

27.35

26.99

25.80

14.52

26.99

27.32

73

29.52

Gross margin%

7.33

6.08

4.83

7.41

6.84

3.85

0.95

0.40

0.40

1.88

5.91

0.95

4.34

57

18.33

Operating margin%

15.84

17.98

15.24

14.78

15.42

17.24

17.76

15.01

17.96

18.93

25.55

17.76

16.54

87

27.89

Net margin%

26.41

25.27

25.72

24.69

22.86

21.06

21.43

20.73

18.44

16.56

8.50

20.73

22.14

46

30.87

P/E ratio (avg)x

27.85

26.27

22.98

21.46

22.65

19.46

21.23

22.39

21.70

21.17

8.542

21.23

22.04

74

20.77

EV/EBITx

29.30

33.46

33.81

34.19

34.47

35.89

35.91

40.67

39.40

38.13

11.73

38.13

35.18

71

26.92

FCF yield (avg)%

11.07

11.90

10.07

7.85

9.83

8.37

8.88

6.11

6.93

4.67

4.88

6.93

8.62

38

2.19

FCF margin%

8.00

9.72

11.82

11.63

12.27

11.34

10.38

10.29

8.64

7.43

9.95

10.29

10.33

69

1.422

FCF / Net incomex

1.165

1.118

0.994

0.931

0.814

0.868

0.831

0.881

0.871

0.780

1.741

0.868

0.876

59

7.16

ROIC%

30.04

30.51

33.09

30.33

27.36

28.37

28.29

25.73

23.06

21.50

14.22

25.73

28.33

42

16.95

Return on equity%

10.40

9.91

7.69

10.35

7.63

9.36

9.76

12.26

11.79

8.82

10.46

9.76

9.83

24

25.09

Return on assets%

10.89

10.81

9.72

12.21

10.59

11.15

8.22

8.24

11.00

11.40

5.31

11.00

10.85

6

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

0.71%

1.11%

—

28.46

EPS growth%

4.21

3.40

3.37

6.30

4.49

1.52

0.40

0.40

0.40

0.40

9.45

0.40

2.44

37

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

4.82%

(0.93%)

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

2.70%

6.17%

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

4.42%

7.27%

—

10.76

Div yield (avg)%

14.91

14.75

15.91

17.81

16.13

15.14

14.30

15.30

14.32

12.09

18.12

14.32

15.02

95

26.06

Payout ratio%

10.64

8.39

6.34

6.75

4.56

2.81

2.89

1.69

2.76

5.02

21.98

2.81

4.79

46

120.3

Shares (diluted)M

166.4

169.2

193.7

207.5

193.9

204.8

227.6

252.4

262.3

279.0

120.1

7.54%

5.64%

65

8.16

Buyback yield%

19.12

18.74

21.38

18.87

20.70

18.44

15.69

17.57

19.14

17.34

10.79

17.57

18.81

55

0.172

D/E ratiox

0.373

0.413

0.415

0.427

0.375

0.384

0.415

0.384

0.423

0.386

0.936

0.386

0.399

14

0.016

Enterprise value$M

0.029

0.034

0.037

0.036

0.039

0.046

0.051

0.053

0.062

0.062

0.071

10.05%

9.91%

69

0.037

LT debt$M

0.033

0.032

0.033

0.034

0.038

0.043

0.042

0.047

0.053

0.050

0.053

5.97%

3.73%

30

Peers (US$0.243M)

Cap (US$)

PE

Anatara Lifesciences…

1.736M

—

Nexalis Therapeutics…

1.390M

—

Propanc Biopharma, Inc.

1.121M

—

0.243M

—

Capital

TTM

5Y

10Y

Leveragex

3.761

1.975

2.225

EBIT/Intx

1.078

0.164

0.130

Own earn%

(2.04)

27.37

39.31

Sh yield%

18.92

32.87

33.53

Owners

Insiders/Inst%

14.51

28.72

Short interest%

1.89

SBC / revenue%

2.65

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

14

Op margin range%

15–19

$1 testx

—

Incr. ROIC%

4

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$0.071M

7.06%

1.00×

Cost of revenue

$0.049M

6.89%

0.98×

Operating expenses

—

8.22%

1.11×